Breaking Finance News

Shire PLC (LON:SHP) has been reiterated to Overweight in a statement by JP Morgan Cazenove earlier today.

JP Morgan Cazenove has reiterated Shire PLC (LON:SHP) to Overweight in a statement released on Friday April 21, 2017.

On 04/19/2017, Credit Suisse released a statement on Shire PLC (LON:SHP) maintained the target price at 5,400.00GBX that suggested an upside of 0.17%.

Having a price of 4,480.50GBX, Shire PLC (LON:SHP) traded 0.48% higher on the day. With the last close down -5.14% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. SHP has recorded a 50-day average of 4,728.57GBX and a two hundred day average of 4,712.13GBX. Trade Volume was down over the average, with 531,200 shares of SHP changing hands under the typical 2,256,140

Recent Performance Chart


Shire PLC has PE ratio of 107.97 with a one year low of 2,707.19GBX and a one year high of 5,377.00GBX and has a market capitalization of 0 GBX.

A total of 18 analysts have released a report on Shire PLC. Six analysts rating the company a strong buy, sixteen analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 73.73GBX.

General Company Details For Shire PLC (LON:SHP)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.